[If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
Schwinger
R H
RH
Klinik III für Innere Medizin, Labor für Herzmuskelphysiologie und Molekulare Kardiologie, Universität Köln. Robert.Schwinger@medizin.uni-koeln.de
Brixius
K
K
D008841:Actin Cytoskeleton / Q000187:drug effects / Q000502:physiology*; D002118:Calcium / Q000378:metabolism*; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects / Q000503:physiopathology*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006835:Hydrazones / Q000494:pharmacology / Q000627:therapeutic use; D009206:Myocardium / Q000378:metabolism* / Q000648:ultrastructure; D010101:Oxygen Consumption; D011724:Pyridazines / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use; D000077464:Simendan; D013829:Thiadiazines / Q000494:pharmacology / Q000627:therapeutic use
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D011804:Quinolines; D013829:Thiadiazines; C070609:EMD 53998; D000077464:Simendan; C041648:pimobendan; D002118:Calcium